Triple-negative breast cancer (TNBC) is a distinct molecular subgroup of breast cancer characterized by the absence of expression of estrogen receptors, progesterone receptors, and human epidermal growth factor 2 (HER2). This form of cancer occurs in 10-20% of all breast cancer cases and is generally more aggressive than other subtypes. TNBC is more often diagnosed in younger women and has a higher risk of recurrence and metastasis, which complicates its treatment and will affect its prognosis. Due to the lack of specific targets for hormonal therapy and anti-HER2 treatment, treatment options are more limited, highlighting the need for further research in this area.
History of the disease and interesting historical facts
Triple-negative breast cancer was identified as a distinct subgroup in the early 21st century, although breast cancer research has been going on for centuries. The earliest references to breast cancer are found in ancient medical texts, including the works of Hippocrates and Avicenna. However, it was not until the 2000s that doctors were able to clearly classify the different molecular subgroups. In 2004, a paper was published that defined the molecular cellular signature of triple-negative cancer, which was a major step forward in the diagnosis and treatment of this form of the disease. Researchers began to realize that triple-negative cancer not only behaved differently, but also required a different approach to treatment.
Epidemiology
According to the American Cancer Society, triple-negative breast cancer accounts for approximately 15% of all breast cancer cases in the United States. It is significantly more common among women of African descent and among younger women. Epidemiological studies show that women under 40 have a 2-3 times higher risk of developing triple-negative cancer compared to their peers. According to statistics, there were approximately 20,000 new cases of triple-negative breast cancer in the United States in 2021, confirming its prevalence.
Genetic predisposition to this disease
Genetic predisposition to triple-negative breast cancer is often linked to mutations in the BRCA1 and BRCA2 genes. Women with mutations in these genes have a significantly increased risk of developing breast and ovarian cancer. Research has shown that about 15-20% of all triple-negative breast cancer cases are linked to mutations in BRCA1, highlighting the importance of genetic testing. Other genes, such as PALB2, TP53, and CHEK2, have also been linked, which may also increase the risk of developing this type of cancer.
Risk factors for the development of this disease
Risk factors for triple-negative breast cancer can include both genetic and environmental factors. Physical risk factors include:
- Age - higher risk in women under 50 years of age.
- Ethnicity - More common among African American women.
- Family history of breast cancer - having relatives with the disease increases your risk.
Chemical risk factors include:
- Exposure to radiation, especially when treating other types of cancer.
- Use of hormone replacement therapies, which may affect estrogen levels.
- Alcohol consumption and smoking, which are associated with an increased risk of various tumors.
Diagnosis of this disease
Diagnosis of triple-negative breast cancer begins with a clinical examination and medical history. The main symptoms include:
- Lumps in the breast or armpit area.
- Changes in the shape or size of the breasts.
- Discharge from the nipple.
- Skin changes such as redness, ulcers, or "orange peel" appearance.
Laboratory tests include:
- Biopsy for histological analysis of tumor tissue.
- Immunohistochemical tests to determine hormone receptors and HER2 status.
Radiological examinations are an important component of diagnostics. They include:
- Mammography to visualize changes in the mammary gland.
- Breast ultrasound to evaluate tumors.
- Magnetic resonance imaging (MRI) for more detailed examination.
Differential diagnosis includes exclusion of other types of breast cancer and benign lesions.
Treatment
Treatment of triple-negative breast cancer requires a comprehensive approach and may involve several modalities. The main treatment method is surgery, which can range from partial breast resection to mastectomy. Pharmacological treatment usually includes:
- Chemotherapy is the most common treatment because triple-negative cancer is sensitive to this type of therapy.
- Immunotherapy - new methods based on the use of immuno-oncological agents such as Pembrolizumab.
Other treatments may include radiation therapy, especially after surgery to prevent recurrence, and participation in clinical trials where new drugs and therapies are tested.
List of medications used to treat this disease
Some of the main drugs used to treat triple-negative breast cancer include:
- Cyclophosphamide
- Doxorubicin
- Paclitaxel
- Conveitmizumab (Atezolizumab)
- Debumetozumab (Durvalumab)
These drugs are usually used in various combinations depending on the stage of the disease and the general clinical situation of the patient.
Disease monitoring
Monitoring of triple-negative breast cancer involves regular follow-up examinations and testing to detect possible recurrence. Typically recommended tests include:
- Clinical and laboratory monitoring every 3-6 months during the first 2-3 years after treatment.
- Mammogram and ultrasound every 6-12 months.
The prognosis for patients with triple-negative breast cancer varies depending on many factors, including stage at diagnosis and response to treatment. Complications can arise from both the disease itself and the treatment, including secondary tumors and cardiovascular complications.
Age-related features of the disease
Triple-negative breast cancer is more common in younger women, especially those aged 40-49. In women over 60, the incidence rate decreases. Younger patients face more aggressive forms of cancer and larger lesions, which makes their treatment more difficult. Also, in older women, the disease may be less aggressive, but concomitant pathologies may affect the choice of therapy.
Questions and Answers
- What are the main symptoms of triple negative breast cancer? The main symptoms include lumps in the breast, changes in breast shape, and discharge from the nipple.
- How is triple negative breast cancer diagnosed? Diagnostics include mammography, ultrasound and tumor biopsy for histological analysis.
- What are the main treatments for triple negative breast cancer? The main treatment methods are surgery, chemotherapy and immunotherapy.
- What is the prognosis for women with triple negative breast cancer? Prognosis depends on the stage of the disease and response to treatment, but triple-negative cancer has a high risk of recurrence.
- Is there a genetic predisposition to triple negative breast cancer? Yes, mutations in the BRCA1 and BRCA2 genes significantly increase the risk of developing this type of cancer.
